Loading...
NPI 1477925188 · Kailua Kona, HI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
S&g Labs Hawaii LLC is a clinical medical laboratory provider located in Kailua Kona, Hawaii. This profile covers 5 Medicare and 45 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | S&g Labs Hawaii LLC |
| Address | 75-240 Nani Kailua Dr |
| City | Kailua Kona |
| State | HI |
| ZIP | 96740 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 21, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $15.1M |
| Medicare | $292.7K |
Service mix and operational focus: Billing is concentrated in clinical toxicology and high-throughput laboratory drug testing, with definitive panels (G0481, G0482, G0480) and presumptive screens (80307) dominating both payers’ top lists. Medicare top codes descriptions emphasize GC/MS and LC/MS definitive testing and specimen validity, while Medicaid activity also includes large volumes of COVID PCR and collection codes (U0004, G2023), indicating the lab operates both forensic/toxicology workflows and scalable infectious-disease testing pipelines.
Medicare revenue concentration: This provider reports $292.7K in total Medicare revenue and its top three Medicare codes account for 82.7% of that Medicare revenue. The Medicare top codes are G0481, 80307, and G0482, which together make up the majority of Medicare receipts and show the practice’s Medicare footprint is narrowly focused on drug-testing services.
Medicaid revenue concentration: The provider reports $15.1M in total Medicaid revenue with the top three Medicaid codes accounting for 67.5% of Medicaid revenue. The Medicaid top revenue drivers are 80307 ($3.9M), G0481 ($3.8M), and G0482 ($2.4M), confirming that presumptive and definitive drug testing are the primary revenue streams under Medicaid.
Payer mix and scale: The provider’s Medicaid revenue ($15.1M) substantially exceeds Medicare revenue ($292.7K), indicating an effectively Medicaid-dominant payer mix rather than balanced dual-payer reliance. Analysts should treat this entity as primarily a Medicaid-facing lab when assessing contracting risk and market impact, with Medicare activity present but comparatively small in scale.
Competitive standing — Medicare: National ranks for the top Medicare codes place the provider at relatively high percentiles (for example, G0481 at the 95th percentile and 80307 at the 96th percentile), but the dataset labels these volumes as "typical, unremarkable" for the codes. That pattern suggests the provider is a noticeable but not uniquely dominant national participant for those specific Medicare toxicology services.
Competitive standing — Medicaid (state-level): In Medicaid, the provider is a dominant statewide player on core codes, ranking #1 in-state for 80307, G0481, G0482 and several other panels; 80307 and G0480 are specifically flagged as "extreme outlier, far above typical state volume," which characterizes the provider as a major in-state laboratory for drug screening. Multiple top codes also rank in the state 100th percentile, signaling market-leading volumes for standard toxicology panels.
High-volume operational signals and claim counts: Medicaid claim counts are large for core services (for example, 80307 has 103.2K claims and G0481 has 54.3K claims), which aligns with the high Medicaid dollar totals and implies high-throughput, repeat screening workflows. The presence of substantial COVID testing claims (U0004 with 16.8K claims and $957.1K revenue, and G2023 with 12.3K claims and $222.2K revenue) further supports the lab’s capacity to process large volumes across different test types.
Tenure and market presence: The provider’s NPI was enumerated on 2015-10-21 (~11 years ago), indicating an established operation with multiple years to scale Medicaid relationships and testing volume. Given the concentrated revenue mix and sustained high claim counts in-state, the provider appears to have built a stable, Medicaid-centric testing business over that period.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 720 | $150 | $108.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,320 | $60 | $79.4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 290 | $190 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 460 | $110 | $50.5K |
| 82977 | The lab analyst measures the gamma–glutamyltransferase enzyme, typically in a serum specimen. This enzyme is elevated in conditions that affect the liver and the bile ducts, as well as primary and… | 20 | $10 | $110 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
45 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 103,220 | $40 | $3.9M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 54,330 | $70 | $3.8M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 24,590 | $100 | $2.4M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 41,270 | $50 | $2.1M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 16,790 | $60 | $957.1K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,480 | $90 | $509.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12,350 | $20 | $222.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 9,030 | $20 | $153.5K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 5,390 | $20 | $86.2K |
| 80365 | The lab analyst measures the amount of or detects the presence of oxycodone, a synthetic opioid pain medication, in a patient specimen. | 5,240 | $20 | $83.9K |
Showing 1–10 of 45
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
45 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 10 | 9,340 | $100 | $1.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 3,320 | $70 | $1.3M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 9,110 | $90 | $996.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 30 | 2,500 | $40 | $455.4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 10 | 130 | $60 | $320.4K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 1 | 10 | 2,210 | $130 | $295.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 20 | 720 | $40 | $165.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3 | 10 | 4,150 | $10 | $121.1K |
| 82570 | The lab analyst measures the amount of creatinine, in a patient specimen, other than blood. Creatinine is the waste material generated by the muscle tissue produced from the breakdown of creatine… | 4 | 10 | 2,730 | $10 | $104.1K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 1 | 10 | 2,870 | $30 | $92.7K |
Showing 1–10 of 45
Other providers in the same ZIP code as S&g Labs Hawaii LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.